Center-Authored Papers

Filters: Author is Becker, P S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
Miller CP, Rattray K, Zhang Y, Wood BL, Burwick N, Chien S, Bensinger WI, Blau CA, Becker PS.  2012.  Evaluating surface erythropoietin receptor in multiple myeloma.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 26(8):1883-6.
I
Zhou Y, Wood BL, Walter RB, Becker PS, Percival M-E, Bar M, Shaw C, Gardner K, Hendrie P, Abkowitz J et al..  2017.  Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed? Leukemia. Abstract
L
Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR et al..  2015.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.. Leukemia.
M
Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR, Becker PS.  2015.  Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.. Blood cancer journal. 5:e302. Abstract
Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL et al..  2017.  Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.. Leukemia. Abstract
Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B et al..  2016.  A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.. Bone marrow transplantation. Abstract
P
Becker PS, Gooley TA, Green DJ, Burwick N, Kim TY, Kojouri K, Inoue Y, Moore DJ, Nelli E, Dennie T et al..  2016.  A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.. Blood cancer journal. 6:e422.
Becker PS, Taylor JA, Trobridge GD, Zhao X, Beard BC, Chien S, Adair J, Kohn DB, Wagner JE, Shimamura A et al..  2010.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.. Gene therapy. 17(10):1244-52. Abstract
Roshal M, Chien S, Othus M, Wood BL, Fang M, Appelbaum FR, Estey EH, Papayannopoulou T, Becker PS.  2012.  The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.
R
Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK, Green DJ, Press OW, Lill M, Ifthikharuddin JJ et al..  2016.  A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.. Bone marrow transplantation. 51(1):67-71. Abstract